Conv. Plasma
Nigella Sativa
Peg.. Lambda

All HCQ studies
Meta analysis
Home COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  

Influence of conflicts of interest on public positions in the COVID-19 era, the case of Gilead Sciences

Roussel et al., New Microbes and New Infections, Volume 38, doi:10.1016/j.nmni.2020.100710
Jun 2020  
  Source   PDF   All Studies   Meta AnalysisMeta
Shows a correlation (Spearman test, p = 0.017) between the amount received from Gilead Sciences and public opposition to the use of HCQ in France.
Roussel et al., 6 Jun 2020, peer-reviewed, 2 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Influence of conflicts of interest on public positions in the COVID-19 era, the case of Gilead Sciences
Y Roussel, D Raoult
New Microbes and New Infections, doi:10.1016/j.nmni.2020.100710
Funding and gifts from the pharmaceutical industry have an influence on the decisions made by physicians and medical experts. In the context of the coronavirus disease 2019 epidemic, several treatments are available to treat patients infected with the virus. Some are protected by patents, such as remdesivir, others0020stare not, such as hydroxychloroquine. We wanted to observe the possible correlation between the fact, for an academic doctor in infectious diseases, of having benefited from funding by Gilead Sciences, producer of remdesivir, and the public positions taken by this doctor towards hydroxychloroquine. Our results show a correlation (Spearman test, p = 0.017) between the amount received from the Gilead Sciences company and public opposition to the use of hydroxychloroquine in France. This should open up the debate on the role of the interest links of doctors with pharmaceutical companies in the medical and scientific public debate.
Conflicts of interest There is no conflict of interest.
Blumenthal, Doctors and drug companies, N Engl J Med
Cao, Wang, Wen, Liu, Wang et al., A Trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19
Chen, Hu, Zhang, Jiang, Han et al., Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial, medRxiv, doi:10.1101/2020.03.22.20040758
Chen, Liu, Lui, Liu, Xu et al., A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19), J Zhejiang Univ (Med Sci, doi:10.3785/j.issn.1008-9292.2020.03.03118
Dana, Loewenstein, A social science perspective on gifts to physicians from industry, JAMA
De Novales, Ramírez-Olivencia, Estébanez, De Dios, Herrero et al., Early hydroxychloroquine is associated with an increase of survival in COVID-19 patients: an observational study, Preprints, doi:10.20944/preprints202005.0057.v1
Dejong, Aguilar, Tseng, Lin, Boscardin et al., Pharmaceutical industry-sponsored meals and physician prescribing patterns for medicare beneficiaries [published correction appears in, JAMA Intern Med
Edwards, Remdesivir shows promising results for coronavirus
Friedman, There's No such thing as a free lunch
Gautret, Lagier, Parola, Hoang, Meddeb et al., Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study, Travel Med Infect Dis
Gautret, Lagier, Parola, Hoang, Meddeb et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents
Gibbons, Landry, Blouch, Jones, Williams et al., A comparison of physicians' and patients' attitudes toward pharmaceutical industry gifts, J Gen Intern Med
Huang, Li, Xiao, Liang, Pang et al., None, doi:10.1101/2020.04.26.20081059v1
Huang, Tang, Pang, Li, Ma et al., Treating COVID-19 with chloroquine, J Mol Cell Biol, doi:10.1093/jmcb/mjaa014
Katz, Caplan, Merz, All gifts large and small: toward an understanding of the ethics of pharmaceutical industry gift-giving, Am J Bioeth
Lexchin, Interactions between physicians and the pharmaceutical industry: what does the literature say?, CMAJ
Magagnoli, Narendran, Pereira, Cummings, Hardin et al., Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19, medRxiv, doi:10.1101/2020.04.16.20065920
Mahevas, Tran, Roumier, Chabrol, Paule et al., No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial, medRxiv, doi:10.1101/2020.04.10.20060699
Million, Lagier, Gautret, Colson, Fournier et al., Full-length title: early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: a retrospective analysis of 1061 cases in Marseille, France, Travel Med Infect Dis, doi:10.1016/j.tmaid.2020.101738
Sharma, Vadhariya, Johnson, Marcum, Holmes, Association between industry payments and prescribing costly medications: an observational study using open payments and medicare part D data, BMC Health Serv Res
Steinman, Shlipak, Mcphee, Of principles and pens: attitudes and practices of medicine housestaff toward pharmaceutical industry promotions, Am J Med
Tang, Cao, Han, Wang, Chen et al., Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial, medRxiv, doi:10.1101/2020.04.10.20060558
Wang, Cao, Zhang, Yang, Liu et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res
Wang, Zhang, Du, Du, Zhao et al., Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebocontrolled, multicentre trial, The Lancet, doi:10.1016/S0140-6736(20)31022-9
Watkins, Characteristics of general practitioners who frequently see drug industry representatives: national cross sectional study, BMJ
Yu, Wang, Li, Hydroxychloroquine application is associated with a decreased mortality in critically ill patients with COVID-19, doi:10.1101/2020.04.27.20073379v1
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop